



GCIG RARE TUMOR Working Group

Thursday, May 30, 2013, 3:30 p.m. – 5:30 pm

Huron Room, Doubletree Hotel, Chicago

MINUTES

I.Ray-Coquard (Chair), J.Ledermann (co-Chair)

Attendees: A. Jhingran (RTOG), C.Chu (COGi), C.Scott & M.Friedlander & C.Lee (ANZGOG), I.McNeish & A.Clamp & C.Gourley (MRC-NCRI), E.Gomez (GICOM), J.McAlpine (NCIC CTG), A.Okamoto (JGOG), E.Pujade-Lauraine (GINECO), D.Mezzananica (MITO), E.Witteveen (DGOG), J.Sehouli & A.Mustea (NOGGO), M.Mirza & H. Havsteen (NSGO), A.Oza & S.Welch (PMHC), E. Kohn & B.Greer & D.Gershenson (NCI US), M.Bookman & D. Miller (GOG), E. Shash (EORTC-GCG), R.Zang (SGOG), M.Baumann (AGO-De), R.Glasspool (SGCTG), J.Schink (ISSTD), K.Fujiwara (GOTIC), A.Zeimet (AGO-Au).

WELCOME, INTRODUCTIONS, CONFLICTS OF INTEREST DISCLOSURES

AGENDA

- **Call to Order and Welcome**
- **Review of Minutes of Leiden MEETING 2012**
- **Update on GCIG Rare Tumor Initiative (I Ray-Coquard & J Ledermann)**
- **Update of rare gynecologic cancer GCIG meeting London Nov 2013 (I Ray-Coquard & J Ledermann)**
- **New projects**
- **Other Business**
- **Adjournment**

1 GCIG Rare Tumor statements:

20 requested:

Topics	leader Group	Coordinator	Co Coordinator	Step
Ov & Ut carcinosarcoma	GINECO	D Berton Rigaud		Validated by Chairmans & 2 nd draft waited
low malignant potential tumors	AGO	P Harter		Waiting for the 1st draft
low grade serous carcinoma	MRC	C Gourley	D Gershenson	Under circulation for validation
Sex cord tumor	GINECO	I Ray Coquard	N Colombo	All +
germ Cell Tumor	GOG	J Brown	M Seickl	Under circulation for validation
squamous Ov carcinoma	SGCTG	R Glasspool	Antonio Gonzales	Under circulation for validation
Small Cell carcinoma cervix	GOTIC	K Fujiwara	N Reed	Under review by co coordinator
small cell carcinoma Ovarian	EORTC	N Reed	P Pautier	Validated by Chairmans & 2 nd draft waited
vulvar & vagina non squamous carcinoma	US NCI	M Leitao	Xi Cheng	All +
ovarian carcinoid tumor	GICOM	E Gomez	N Reed	Under circulation for validation

Topics	leader Group	Coordinator	Co Coordinator	Step
pseudomixoma peritonei & mucinous carcinoma	MRC/NCRI	J Ledermann	D Gershenson	Waiting for the 1st draft
clear cell carcinoma Ovary	JGOG	A Okamoto	R Glasspool	Under circulation for validation
clear cell carcinoma Cervix & Ut	GOTIC	K Fujiwara & Dr Hasegawa		Under circulation for validation 2 nd draft waited
trophoblastic diseases	MITO	K Larusso	M Seickl	Validated by Chairmans & 2 nd draft waited
low grade endometrial stromal sarcoma	EORTC	F Amant		All +
HGUS	GINECO	P Pautier		Validated by Chairmans & 2 nd draft waited
uterine papillary serous carcinoma	JGOG	S Sagae	A Viswanathan	Under review by co coordinator
adenosarcoma	ANZGOG	M Friedlander		Under circulation for validation
Ut & Ov leiomyosarcoma	US NCI	M Hensley		All +
glandular carcinoma of cervix	GOTIC	K Fujiwara		Under circulation for validation

SUMMARY

Ov & Ut carcinosarcoma
low malignant potential tumors
low grade serous carcinoma
Sex cord tumor
germ Cell Tumor
squamous Ov carcinoma
Small Cell carcinoma cervix
small cell carcinoma OV
vulvar & vagina non squamous carcinoma
ovarian carcinoid tumor
pseudomixoma peritonei & mucinous carcinoma
clear cell carcinoma Ovary
clear cell carcinoma Cervix & Ut
trophoblastic diseases
low grade endometrial stromal sarcoma
HG uterine sarcoma
uterine papillary serous carcinoma
adenosarcoma
Ut & Ov leiomyosarcoma
glandular carcinoma of cervix

20 DOCUMENTS:

18 sent at least a first draft
(MEoc, BL waiting)

4 completely finalized

4 2nd draft waiting

7 under validation by group/chairs

3 under review by co coordinator

Questions & discussions

- **Definition of the project :**
 - GCIG rare tumor consensus review
- **Relation with other groups/societies:**
 - WSN, ISSTD, EOSTD,
- **Next steps for publication:**
 - Review by national groups will be done on Sept
 - Finalization by an “editing board” I R-C, JAL, M. Friedlander, K Lorusso, E Kohn, D Gershenson, A Oza for October
 - Final version posted on GCIG website
- **Next meeting specifically dedicated to review documents ESMO meeting (Amsterdam 2013)**

Definition of the project :

GCIG rare tumor consensus review

- As not guidelines and not always in consultation with international groups such as sarcoma/TDG etc, these should be GCIG consensus Review Group documents posted on web site
- A commentary for eg IJGC demonstrating how these were written and what their function is.
- Idea would be to revise group documents every year or two.

Next steps:

- These need to be sent to individual groups for circulation within membership as groups see fit for comment. Then back to RTWG for final version that should be finally agreed by groups before being posted on the GCIG web site
- Acknowledgements of authors should be on the web site as well as other societies if they have endorsed.
- A review committee should be set up to manage the finalization of the group documents before posting on the GCIG web site.

I R-C

JAL

Michael Friedlander

Ketta Lorusso

Elise Kohn

David Gershenson

Amit Oza

Agreed to do this.

2. London RTwg Brainstorming Program

GCIG Rare Tumors Planning Meeting – London, 16 Nov 2013

Participants: GCIG groups (2-3 representatives for each group) & invited speakers / experts in the field

Objectives:

- To define current guidelines for rare gynecologic tumors;
- To define control arm for present and future clinical trials involving rare cancer;
- To identify national & international barriers for trials dedicated to rare gynecologic cancers
- To summarize and prioritize key issues for research and agree new set of trial concepts to address the key issues in several rare tumors
- To prioritize and design 3 international initiatives in rare gynecologic cancer

Developing Agenda :

GCIG Rare Tumors Planning Meeting – London, 16 Nov 2013

- Welcome, objectives
- Review & validation of the GCIG rare cancers documents
- Main statistical issues for ongoing & future trials
- Main harmonization/Regulation issues
- Complexities of collecting samples across international boundaries -
- Example of successful story from other cancers/groups
- II part : 3 working groups sessions
 - 1) relatively rare tumors
 - 2) rare tumors
 - 3) very rare tumors

- First part should include talk about complexities of collecting samples across international boundaries. – legal, IP, etc. Possible speakers include Clare Scott or Jalid Sehouli (EUTROC experience)

- 3 working sessions:

These should be methodologically led, taking a tumor for each of the three sessions:

1. Eg: pap serous endo Ca or adenoCa cervix as an example of a RCT. Would need biology input into this too
2. Rarer tumor type where novel design methodologies would be key (eg: adaptive design) (eg: SCT)
3. The very rare where there is no possibility of a RCT. Registry data should be decided (work with FIGO who are developing a minimum dataset). Could be linked to Cartwheel type project to capture as many patients as possible and build knowledge iteratively.

Importance of path input emphasized by David Millan- need to work on getting expert review ? telepathology

Workshop 1' Relatively Rare tumour'

Possible co-chairs: K.Fujiwara & R.Glasspool

Need some definitions and perhaps a list compiled from Rare Cancer? FIGO data etc – but incidence varies throughout the world

Workshop 2 'Rare' tumors

Possible co-chairs: A Oza & M Parmar

Workshop 3 'Very rare'

Possible co-chairs: D. Gershenson & C. Scott or M. Friedlander

Need to have biostatisticians in groups 1 & 3 to help (J Paul & M Brady)

D Gershenson, A Oza, K Fujiwara, R Glasspool, M Parmar confirmed to be present; C Scott not sure yet.

3 **Other Business:**

GCIG on –going trials or potential trials

- Alienor (GINECO)
- GOG0275 (UC1005): A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia. J Schink

4 **Adjourn**